Drug intelligence / Profile preview

lactobacillus gasseri CCFM1201

Development stage: Preclinical
Lead developer: Jiangnan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Intravaginal (topical)

Overview

Lactobacillus gasseri CCFM1201 is a specific probiotic strain of the species Lactobacillus gasseri. It has demonstrated significant inhibitory effects against Gardnerella vaginalis, the primary pathogen responsible for bacterial vaginosis (BV). In both in vitro and in vivo models, L. gasseri CCFM1201 inhibits biofilm formation by G. vaginalis, reduces sialidase activity, modulates inflammatory cytokines such as tumor necrosis factor-α and interleukin-1β, and improves histopathological features of BV including epithelial cell exfoliation and tissue inflammation. The strain can be formulated into microbial inocula, medicinal products (including drugs), or female hygiene products for the prevention or treatment of bacterial vaginosis and maintenance of vaginal health[2][4][1]. Its mechanism involves competitive exclusion of pathogens through adhesion to epithelial cells, production of organic acids to maintain acidic pH (<4.5), secretion of antimicrobial substances, and modulation of local immune responses[2][3][4].

Other names: 格式乳杆菌CCFM1201格氏乳杆菌CCFM1201

Targets

G. vaginalis (Gardnerella vaginalis)

Beyond the preview

Go deeper on lactobacillus gasseri CCFM1201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus gasseri CCFM1201.

Explore the full profile